Author

Haeseong Park

Dana-Farber Cancer InstituteORCID 0000-0002-3430-8463Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Akhouri Kishore RaghawaniD· 1 shared Andrew J. AguirreiD· 1 shared Daulet AitymbayeviD· 1 shared David J. CheniD· 1 shared Eun Hee JungiD· 1 shared Eunjung Alice LeeiD· 1 shared Heejung ChaeiD· 1 shared Ja-Lok Ku· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Akhouri Kishore RaghawanORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

VEGFR2 blockade overcomes acquired KRAS G12D inhibitor resistance driven by PI3Kγ activation

Sung‐Hyun Hwang, Mingyun Bae, Ji‐Won Kim, Seung Yoon Hyun, Kui‐Jin Kim, Joshua H. Choe, Min Jung Kim, Ji Won Park, Seung‐Yong Jeong, Songji Choi, Woochan Park, Jeongmin Seo, Heejung Chae, Min-Su Kang, Eun Hee Jung, , Keun‐Wook Lee

This paper identifies VEGFA-VEGFR2 signaling driven by PI3Kγ activation as a mechanism of acquired resistance to KRAS G12D inhibitors and shows that blocking this pathway restores drug sensitivity in resistant cancer models.

bioRxiv · Sep 16, 2025 · PreprintCancer Biology

Chemical perturbations impacting histone acetylation governcolorectal cancer differentiation

Pornlada Likasitwatanakul, Zhixin Li, Khoa Tat Doan, Sándor Spisák, Akhouri Kishore Raghawan, Qi Liu, Priscilla Liow, Sunwoo Liv Lee, David J. Chen, Pratyusha Bala, Pranshu Sahgal, Daulet Aitymbayev, Jennifer S. Thalappillil, Malvina Papanastasiou, William Hawkins, , Nilay S. Sethi

The paper identifies HDAC1/2 inhibition as a method to promote colorectal cancer differentiation through H3K27ac gains, which can be reversed by blocking EP300.

Gastroenterology · Jul 7, 2025Peer-reviewedCancer Biology